Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 4/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.66 |
| ▸ | DRD1 | P21728 | 2/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.66 |
| ▸ | BCL2 | P10415 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9253409 | 0.93 | CYP2D6 (0.61) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL42119 | 0.89 | OPRM1 (0.59) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7668121 | 0.87 | CHRM2 (0.83) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11354393 | 0.85 | OPRM1 (0.60) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9256149 | 0.83 | OPRM1 (0.55) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9252844 | 0.83 | OPRM1 (0.57) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9250178 | 0.82 | KCNH2 (0.52) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6824843 | 0.82 | CYP2D6 (0.71) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13309488 | 0.82 | CYP2D6 (0.71) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13309489 | 0.82 | CYP2D6 (0.71) | DRD3KCNH2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601674-B1 | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-08 | — | — | EP | claimed |
| JP-4712384-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| EP-1601674-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO 4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-07 | — | — | EP | claimed |
| US-6967199-B2 | Substituted diamine derivatives useful as motilin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-11-22 | — | — | US | claimed |
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-07-22 | — | — | US | claimed |
| WO-2004022558-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | JOHNSON SIGMONG G (US) | 2003-10-30 | — | — | US | claimed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-31 | — | — | US | claimed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | claimed |
| US-5470851-A | Antihistamine, anticoagulants | SANKYO COMPANY, LIMITED (JP) | 1995-11-28 | — | — | US | claimed |
| EP-0463873-A1 | Thiazolidinecarboxylic acid amide derivatives having anti-allergic activity, their preparation and their use | Sankyo Company Limited (JP) | 1992-01-02 | — | — | EP | claimed |
| EP-1926721-B1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-04 | — | — | EP | disclosed |
| US-8778956-B2 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| EP-1601674-B1 | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-08 | — | — | EP | disclosed |
| US-7977374-B2 | Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-07-12 | — | — | US | disclosed |
| US-5925642-A | ANTITUMOR, ANTIMETASTASIS AGENTS; DRUG RESISTANCE MODULATORS; SYNERGISTIC MIXTURES WITH ANTIBIOTICS AND CYTOSTATIC AGENTS; SIDE EFFECT REDUCTION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-07-20 | — | — | US | disclosed |
| US-5668131-A | CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-16 | — | — | US | disclosed |
| US-5470851-A | Antihistamine, anticoagulants | SANKYO COMPANY, LIMITED (JP) | 1995-11-28 | — | — | US | disclosed |
| EP-0463873-A1 | Thiazolidinecarboxylic acid amide derivatives having anti-allergic activity, their preparation and their use | Sankyo Company Limited (JP) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | OPRL1, GPR4, ADRA1D | DRD3 111/4885KCNH2 2149/4885SLC6A2 642/4885 |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | DRD3 68/4885KCNH2 4359/4885SLC6A2 915/4885 |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | DRD3 105/4885KCNH2 4003/4885SLC6A2 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.